Licensed Pharmacies•
Fully Online Care•
Free Expedited Delivery•
Dedicated Clinical Team•
HSA/FSA Accepted•
Same-Day Doctor Visits•

BPC-157 and TB-500: Evidence, Rules and Blend Limits

Published November 22, 2026

BPC-157 and TB-500 at a glance

BPC-157TB-500
What it isA 15-amino-acid peptide first isolated from gastric juiceA synthetic peptide related to thymosin beta-4, a protein found in most human cells
Forms allowed under the 2026 HHS policySubcutaneous, intramuscular, oral, topicalSubcutaneous or intramuscular injection only
Human dataAbout 30 people across three small studies40 healthy volunteers given thymosin beta-4 by IV in one safety study
Reported clinic schedule250 to 500 mcg a day under the skin2 to 2.5 mg twice a week for four to six weeks, then less often
FDA-approvedNoNo
WADA statusProhibited (S0, non-approved substances)Prohibited (S2.3, named as a thymosin beta-4 derivative)

The schedules above come from a clinic guide that Rite Aid's peptide pages cite. They are reports of practice. No trial set them.

Why people pair them

In animal studies, the two peptides act on different parts of tissue repair. BPC-157 research centers on blood-vessel growth signals and tendon, ligament and gut healing. Thymosin beta-4 research centers on cell movement and wound repair. The pairing assumes those effects add up.

That assumption has not been tested in people. Rite Aid's guide, updated September 29, 2026, states that no controlled human trial has established whether the stack improves healing, whether one peptide adds value to the other, or which dose and cycle balance benefit and risk.

The closest human data is a 2021 chart review of knee injections. Some patients received BPC-157 alone and some received BPC-157 with thymosin beta-4, placed in the knee joint. Most reported less pain. The study had no control group and too few patients to compare the two approaches.

What the human studies show for each

BPC-157. Two 2025 reviews describe three small studies: the knee injection chart review, a 12-patient bladder pain pilot, and a safety pilot in which two healthy adults received up to 20 mg by IV with no adverse events reported. A systematic review in HSS Journal found no clinical safety data beyond these.

Thymosin beta-4. A 2010 randomized, placebo-controlled study gave IV thymosin beta-4 to four groups of 10 healthy volunteers at 42, 140, 420 and 1,260 mg, first as a single dose and then daily for 14 days. Adverse events were infrequent and mild or moderate, with no dose-limiting toxicity.

One caution on names: products sold as TB-500 may contain a fragment of thymosin beta-4, not the full-length protein that study used. Results from one do not transfer to the other by default.

The blend question

Search results are full of "BPC-157 + TB-500 blend" vials and dose calculators for them. Two points matter before you use one.

The 2026 HHS policy does not cover blends. Holland & Knight's summary lists ten conditions for a pharmacy to compound these peptides. Condition seven: the compounded product contains a single active ingredient from the policy's list. A pharmacy working within the policy dispenses BPC-157 and TB-500 as separate products.

A blend locks the ratio. With two vials, a prescriber can set each dose and each schedule. BPC-157 is reported as a daily injection and TB-500 as twice a week. A single vial forces both onto one schedule, and every change in syringe units changes both amounts at once.

Blend vials sold online as research products sit outside the pharmacy system. No prescription, pharmacy license or certificate of analysis stands behind them.

Safety points to know first

  • Long-term human safety is unknown for both peptides and for the pair.
  • Cancer history needs a conversation. Both peptides affect cell growth and blood-vessel signaling in lab studies. Tell your prescriber about any current or past cancer.
  • A new injury may need a diagnosis first. Pain and swelling can mean a fracture, clot, infection or tear that a peptide will not fix.
  • Athletes face a ban. The World Anti-Doping Agency's 2026 Prohibited List names both. Urine tests can detect BPC-157 for four to five days.
  • Watch injection sites. Redness, warmth, drainage or fever after an injection can signal infection.

For BPC-157 dose figures, see BPC-157 dosage: what studies used. For oral forms, see BPC-157 capsules vs injection.

How Ozari approaches peptide therapy

Ozari Health connects patients with licensed, independent providers who review each medical history before prescribing. Licensed US pharmacies fill the prescriptions. You can see Ozari's current longevity treatments on the vitality page.

Frequently Asked Questions

Can you take BPC-157 and TB-500 together?

Clinics do prescribe them together, and no controlled human trial has tested the combination. A licensed prescriber decides whether the pair fits your case and sets each dose.

What is the Wolverine stack?

It is a nickname for BPC-157 used with TB-500 for injury recovery. The name comes from marketing. The evidence comes from animal studies and uncontrolled clinic reports.

Can BPC-157 and TB-500 be mixed in the same syringe or vial?

Under the 2026 HHS policy, a compounded product must contain a single listed active ingredient, so a pharmacy following the policy supplies them separately. Ask your prescriber and pharmacist before drawing both into one syringe.

What is the BPC-157 and TB-500 dosage?

No trial has set one. A clinic guide cited by Rite Aid reports BPC-157 at 250 to 500 mcg a day and TB-500 at 2 to 2.5 mg twice a week for four to six weeks. Your prescriber sets your dose.

Is TB-500 the same as thymosin beta-4?

Not always. TB-500 is a marketing name, and products sold under it may contain a fragment of thymosin beta-4. The 2026 HHS policy covers TB-500 acetate with a defined identity that the pharmacy must verify.

Are BPC-157 and TB-500 legal?

Neither is FDA-approved. Since October 28, 2026, an HHS interim policy lets state-licensed pharmacies compound each one for a patient-specific prescription under ten conditions. HHS can revisit the policy, and states can set stricter rules.



This article is for informational purposes only and does not constitute medical advice. Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. BPC-157 and TB-500 are not FDA-approved for any use. Individual results vary. Always consult a licensed healthcare provider before starting any prescription medication. Ozari Health is a telehealth platform that connects patients with licensed, independent healthcare providers.

Related Articles